Table S1. Subgroup analysis for select outcomes based on the type of control group across trials.

Comparators	References	Outcomes (network odds ratio with 95% CI)			
		TFG < 3	STR	LVEF[#]	MACEs
Placebo					
	Anisodamine	3.66 (0.97-13.67)	0.35 (0.10-1.28)	-4.85 (-12.21 to 2.53)	4.96 (1.26-21.15)
	Nitroprusside	1.48 (0.77-3.02)	0.69 (0.36-1.19)	-5.25 (-10.89 to 0.47)	1.65 (0.92-3.05)
	Adenosine	1.70 (1.15-2.68)	0.54 (0.35-0.76)	-0.91 (-3.71 to 1.98)	1.59 (1.15-2.24)
	Diltiazem	0.86 (0.11-5.96)	1.20 (0.19-7.38)	3.09 (-7.87 to 14.26)	1.63 (0.22-11.41)
	Verapamil	6.20 (1.99-23.21)	0.69 (0.23-1.82)	-3.15 (-7.61 to 1.56)	1.31 (0.58-3.00)
	Nicorandil	-	-	-	-
	Urapidil	0.30 (0.00-20.00)	0.39 (0.07-2.06)	-3.84 (-9.06 to 1.42)	0.97 (0.02-35.26)
Conventional PPCI alone					
	Anisodamine	4.31 (1.31-13.88)	0.27 (0.08-0.99)	-6.00 (-8.48 to -3.90)	8.52 (2.38-34.98)
	Nitroprusside	2.27 (1.18-4.31)	0.82 (0.23-2.33)	0.47 (-2.93 to 2.61)	1.23 (0.37-3.56)
	Adenosine	1.92 (0.59-6.29)	0.86 (0.29-2.53)	1.50 (-1.26 to 3.67)	0.19 (0.02-1.67)
	Diltiazem	1.98 (0.66-5.75)	0.67 (0.19-2.26)	-0.22 (-3.49 to 2.96)	2.64 (0.66-11.53)
	Verapamil	3.00 (1.24 -7.17)	0.75 (0.23-2.54)	-1.25 (-3.82 to 1.10)	1.71 (0.40-7.65)
	Nicorandil	3.34 (1.50-7.96)	0.28 (0.08-0.97)	0.88 (-1.83 to 2.79)	1.50 (0.62-4.14)
	Urapidil	-	-	-	-

TFG, TIMI flow grade; STR, ST-segment resolution; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; PPCI, primary percutaneous coronary intervention. [#] Values are expressed as mean difference with 95% CI.



Fig. S1 Summary forest plot table for the outcome of major adverse cardiovascular events during short-term follow-up (≤4.5 months). H-H trials, head-to-head trials; black text, network meta-analysis results; grey text, pairwise meta-analysis results; CrI, credible interval; SUCRA, the surface under the cumulative ranking curve; Interventions are displayed by SUCRA percentages; Each intervention in the second column was compared with the intervention listed in the first column.



Fig. S2 Summary forest plot table for the outcome of major adverse cardiovascular events during long-term follow-up (>4.5 months). H-H trials, head-to-head trials; black text, network meta-analysis results; grey text, pairwise meta-analysis results; CrI, credible interval; SUCRA, the surface under the cumulative ranking curve; Interventions are displayed by SUCRA percentages; Each intervention in the second column was compared with the intervention listed in the first column.



Fig. S3 Summary forest plot table for the outcome of major adverse cardiovascular events defined as a composite of death, reinfarction, or revascularization. H-H trials, head-to-head trials; black text, network meta-analysis results; grey text, pairwise meta-analysis results; CrI, credible interval; SUCRA, the surface under the cumulative ranking curve; Interventions are displayed by SUCRA percentages; Each intervention in the second column was compared with the intervention listed in the first column.